---
title: "Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Definition and etiology"
description: "Formulary evidence on Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Definition and etiology. Topics: Disease definition: immune-mediated demyelinating disorder of the peripheral nerves and nerve roots, Typical CIDP and CIDP variants in the EAN/PNS 2021 guideline, Distribution of clinical phenotypes in national cohorts, Etiology: immune triggers and target antigens unidentified in most patients, and 1 further topic. 5 evidence topics quoted from 9 sources."
canonical: "https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description/definition-and-etiology"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Definition and etiology

<a id="heading-2.2.1.1"></a>

## 2.2.1.1 Definition and Etiology

<a id="topic-2.2.1.1-1"></a>

### Disease definition: immune-mediated demyelinating disorder of the peripheral nerves and nerve roots

> “Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a disorder of the peripheral nerves and nerve roots causing limb weakness and sensory deficits”
> “CIDP is considered an immune-mediated disorder although the pathogenesis and aetiology of CIDP remain elusive”

Source: [Broers et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6518865/)

> “Chronic inflammatory demyelinating polyradiculopathy (CIDP) is a symmetric, motor greater than sensory, proximal and distal demyelinating peripheral neuropathy with a slowly progressive or relapsing course.”

Source: [Laughlin et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2707109/)

> “CIDP is caused by primary immune‐mediated demyelination and secondary axonal damage in the peripheral nervous system, resulting in progressive muscle weakness and sensory impairment that led to significant disability”

Source: [Querol et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12361836/)

<a id="topic-2.2.1.1-2"></a>

### Typical CIDP and CIDP variants in the EAN/PNS 2021 guideline

> “Typical CIDP and CIDP variants were distinguished. The previous term "atypical CIDP" was replaced by "CIDP variants" because these are well characterized entities (multifocal, focal, distal, motor, or sensory CIDP).”

Source: [Van den Bergh et al. (2021)](https://onlinelibrary.wiley.com/doi/10.1111/ene.14959)

> “Typical CIDP manifests as symmetrical sensorimotor neuropathy with proximal and distal limb involvement with absent or reduced tendon reflexes. Weakness must be more or less symmetric in all four limbs and the severity of proximal and distal weakness should be similar. Sensory disturbances are to be found in at least two limbs.”
> “The CIDP variants, which were formerly referred to as atypical CIDP variants,”
> “are specific clinical syndromes that share the same signs that are supportive of demyelination and respond to the same therapies and are therefore considered to be on the same disease spectrum as sensorimotor CIDP.”

Source: [van Doorn et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10875175/)

<a id="topic-2.2.1.1-3"></a>

### Distribution of clinical phenotypes in national cohorts

> “Typical CIDP was the most frequent subtype (52%), followed by distal (17%) and multifocal/focal CIDP (17%).”

Source: [Aotsuka et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38408295/)

> “We identified 106 patients with typical CIDP (29%), 62 distal CIDP (17%), 28 multifocal or focal CIDP (7%), four sensory CIDP (1%), 27 sensory‐predominant CIDP (7%), 10 motor CIDP (3%), and eight motor‐predominant CIDP (2%).”

Source: [De Lorenzo et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11235819/)

> “Patients were diagnosed with typical CIDP (69.2%) and variant CIDP (30.8%).”

Source: [Querol et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12361836/)

<a id="topic-2.2.1.1-4"></a>

### Etiology: immune triggers and target antigens unidentified in most patients

> “Though the exact triggers are unclear, diverse immune mechanisms encompassing cellular and humoral pathways are implicated.”
> “However, the trigger(s) for the autoimmune response and the target antigen(s) involved remain elusive in most patients”
> “A systematic screening of antibodies revealed a diverse antibody repertoire in CIDP patients, including those against NF-155 (4.6%), CNTN1 (6.2%), Caspr1/CNTN1 complex (1.5%), P2 (1.6%), and anti-ganglioside antibodies (18.6%).”

Source: [Querol et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9294101/)

<a id="topic-2.2.1.1-5"></a>

### Risk factors: older age, male sex, and diabetes mellitus

> “The incidence rates increased with age for both sexes and were higher in males compared with females aged ≥55 years”
> “The finding that epidemiologic rates of CIDP were higher among males vs. females aged ≥55 years distinguishes CIDP from other autoimmune diseases, which are typically more prevalent in women across the lifespan”
> “The most common comorbidity was diabetes mellitus.”

Source: [Gable et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12880827/)

> “Only 1 of the 23 CIDP patients (4%) also had DM, whereas 14 of 115 age- and sex-matched controls (12%) had DM.”
> “Diabetes mellitus (DM) is unlikely to be a major risk covariate for CIDP, but we cannot exclude a small effect.”

Source: [Laughlin et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2707109/)

## Related pages
- [Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Terms and abbreviations](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/terms-and-abbreviations.md)
- [Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Product information and disease description](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Clinical evidence](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/clinical-evidence.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Economic information and modeling report](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/economics) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/economics.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: References](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/references) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/references.md)
